External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis
The validation process of the budget impact analysis of the incorporation of the drug fingolimod in 2017 resulted in savings of around US$ 82,4 million in relation to the value proposed for incorporation.
Authors
- Márcia Gisele Santos da Costa (ORCID: https://orcid.org/0000-0003-3861-5257)
- Cesar Ricardo Simioni Campello
- Márcia Pinto
Institutions
- Institute of Technology Assessment (AT)
- Institute of Biomedical Science (GB)
- Fundação Oswaldo Cruz (BR)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1186/s12962-025-00698-6
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00